Skip to main content

Illumina Stock Slides 5.53 Percent on Analyst Downgrade

NEW YORK, June 10 (GenomeWeb News) - Shares in Illumina were down 5.53 percent, or $.67, at $11.45 in mid-afternoon trading after an investment bank downgraded the company's stock.

 

Robert W. Baird downgraded the stock to "Neutral" from "Outperform."

 

Also today, investment bank Leerink Swann began covering Illumina with an "Outperform" rating.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.